All News

Know when that pink ribbon makes a difference (and when it doesn't).

As the treatment paradigm shifts for triple-negative breast cancer, PARP inhibitors will continue to play a role.

Subsets of patients with acute lymphoblastic leukemia are getting more personalized care.

After doing well in a phase 3 trial, Stivarga showed the potential to shift the treatment paradigm for previously treated liver cancer.

Scanxiety due to a scheduled or surprise scan or ultrasound can trigger those thoughts and fears of cancer recurrence at any moment.

Women breast cancer survivors explain what they want to hear from the men in their lives.

Yervoy reduced risk of death for patients with high-risk stage 3 melanoma in a recent study.

The addition of immunotherapy did not show an improved progression-free survival for some patients with head and neck cancer.

A new drug combination showed improved progression-free survival for patients with advanced melanoma, according to a recent study.

Patients with DNA mismatch repair deficiency rectal cancer may not necessarily have Lynch syndrome. Expert Yi-Qian Nancy You weighs in on the topic.

Cancer survivor rethinks her home for easier management after cancer.

Choosing active surveillance did not increase stress levels for men with low-risk prostate cancer, according to a recent study.

Michael Choti talks about what kind of advances can be expected in treating liver cancer, including PD-1 inhibitors and neoadjuvant treatment.

A recent trial presented an unexpected survival benefit for patients with high-risk soft tissue sarcoma who were on anthracycline-based neoadjuvant chemotherapy.

Johnson writes about seeing clearly when the storm clouds settle.

Not all breast cancer survivors support this social media campaign.

Findings from a recent trial show that frontline Opdivo did not improve progression-free survival over chemotherapy in certain patients with lung cancer.

In a recent phase 2 trial, Cabometyx showed longer progression-free survival than Sutent in patients with metastatic kidney cancer.

Survivors and patients with cancer had the opportunity to celebrate alongside their friends, family and medical staff at a recent event in New Jersey.

Judith Paice discusses many of the misconceptions that people have about the use of medical marijuana for patients with cancer.

In October, as we recognize Breast Cancer Awareness Month, let us not forget women with dementia. The mammogram, and related cancer treatment, can be controversial for elderly dementia patients. A care team will help with decision making. In my case, with my mother, we chose to follow-up on a very late diagnosis of breast cancer, with no regrets.

A cohort of patients with ovarian cancer saw survival benefit with niraparib in a recent phase 3 study.

Single-agent Keytruda improved survival rates for a group of patients with lung cancer, according to the results of a recent study presented at the 2016 European Society for Medical Oncology (ESMO) Congress.

Patients with CML who are insured by Medicare are choosing to delay potentially life-saving treatment due to high costs.

When it comes to nutrition, conflicting ideas can often cloud vision.

After going through the "Dark Ages," we're approaching the "Golden Age" of kidney cancer care, with more options available than ever, says James Hsieh.

Knowing the risks of ovarian cancer is extremely important. Peter Dottino discusses the risks, symptoms and management of the disease.

Pelvic intensity-modulated radiation therapy (IMRT) showed a decrease in gastrointestinal toxicity in women with cervical and ovarian cancer, according to a recent study.

The FDA granted Alecensa a breakthrough therapy designation to be used in the frontline setting for some patients with non small-cell lung cancer.